TB-500 Fragment


Synthetic heptapeptide fragment of thymosin beta-4 encompassing the actin-binding domain (residues 17-23) with N-terminal acetylation

A synthetic N-acetylated heptapeptide (Ac-LKKTETQ) derived from the central actin-binding domain of thymosin beta-4, investigated for tissue repair, angiogenesis, anti-inflammatory activity, and wound healing through modulation of actin polymerization dynamics and cellular migration.

Abstract

TB-500 Fragment (Ac-LKKTETQ) is a synthetic heptapeptide corresponding to residues 17 through 23 of the endogenous 43-amino acid polypeptide thymosin beta-4, a ubiquitous intracellular G-actin sequestering protein that participates in cytoskeletal organization, cell migration, angiogenesis, and tissue repair. The fragment encompasses the central actin-binding domain of the parent molecule and is N-terminally acetylated to confer resistance to aminopeptidase degradation and to replicate the post-translational modification present on native thymosin beta-4. TB-500 Fragment has been the subject of substantial preclinical investigation since the early 2000s, when Philp et al. (2003) demonstrated that the synthetic LKKTETQ heptapeptide promoted dermal wound repair in db/db diabetic mice and in aged mice at efficacy levels comparable to the full-length thymosin beta-4 molecule, establishing the actin-binding domain as a sufficient pharmacophore for the tissue repair activity of the parent protein. The principal molecular mechanism of TB-500 Fragment is sequestration of G-actin monomers and modulation of actin polymerization dynamics, which promotes cell migration, endothelial tube formation, keratinocyte mobilization, and extracellular matrix remodeling. Downstream signaling involves activation of integrin-linked kinase (ILK), phosphorylation of Akt/protein kinase B, suppression of NF-kappaB-mediated proinflammatory cytokine release, and upregulation of matrix metalloproteinases that facilitate tissue remodeling during wound repair. The pharmacological profile of TB-500 Fragment is therefore characterized by four principal activities: promotion of angiogenesis, acceleration of wound healing, anti-inflammatory modulation, and facilitation of stem and progenitor cell migration. Preclinical evidence in rodent models has demonstrated accelerated dermal wound closure in diabetic and aged animals, cardioprotection following experimental myocardial infarction (demonstrated with the parent thymosin beta-4 molecule in the landmark Bock-Marquette et al. 2004 Nature study), promotion of hair follicle stem cell activation and hair growth (Philp et al. 2004), and anti-inflammatory activity through suppression of NF-kappaB nuclear translocation and reduction of TNF-alpha and IL-1-beta production. Human clinical data for the heptapeptide fragment itself are limited; the majority of clinical evidence derives from the full-length thymosin beta-4 molecule, which has been evaluated in Phase 2 and Phase 3 clinical trials for dry eye disease (RGN-259, RegeneRx Biopharmaceuticals) and in Phase 2 studies for neurotrophic keratopathy. The Phase 2 dry eye trial demonstrated statistically significant improvements in ocular discomfort (35.1 percent reduction) and corneal fluorescein staining (59.1 percent reduction) relative to vehicle control. The Phase 3 ARISE program in dry eye disease did not meet co-primary endpoints, though statistically significant improvement in ocular grittiness was observed. TB-500 Fragment is not approved by any regulatory authority for human therapeutic use. It is classified as a prohibited substance by the World Anti-Doping Agency under Sections S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) and is prohibited in equine racing competition by multiple national racing authorities. Preclinical data indicate that tissue-level effects persist substantially longer than plasma residence, consistent with the intracellular mechanism of action. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph